HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
RP
These findings provide insight for clinicians transitioning patients with RP to rilonacept monotherapy, affirming a strategy of rapid cessation of oral therapies. These findings suggest efficacious IL-1 blockade may render standard oral therapies redundant, supporting accelerated withdrawal.